Skip to main content

Advertisement

SpringerLink
Log in

Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations

  • Lymphomas (L Gordon, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Post transplant lymphoproliferative disorder (PTLD) is a heterogeneous disease that may occur in recipients of solid organ transplants (SOT) and hematopoietic stem cell transplant. The risk of lymphoma is increased 20–120% compared with the general population with risk dependent in part on level of immune suppression. In addition, recent data have emerged, including HLA and cytokine gene polymorphisms, regarding genetic susceptibility to PTLD. Based on morphologic, immunophenotypic, and molecular criteria, PLTD are classified into 4 pathologic categories: early lesions, polymorphic, monomorphic, and classical Hodgkin lymphoma. Evaluation by expert hematopathology is critical in establishing the diagnosis. The aim of therapy for most patients is cure with the concurrent goal of preservation of allograft function. Given the pathologic and clinical heterogeneity of PTLD, treatment is often individualized. A mainstay of therapy remains reduction of immune suppression (RI) with the level of reduction being dependent on several factors (e.g., history of rejection, current dosing, and type of allograft). Outside of early lesions and/or low tumor burden, however, RI alone is associated with cure in a minority of subjects. We approach most newly-diagnosed polymorphic and monomorphic PTLDs similarly using frontline single-agent rituximab (4 weeks followed by abbreviated maintenance) in conjunction with RI. Frontline combination chemotherapy may be warranted for patients with high tumor burden in need of prompt response or following failure of RI and/or rituximab. Due to chemotherapy-related complications in PTLD, especially infectious, we advocate comprehensive supportive care measures. Surgery or radiation may be considered for select patients with early-stage disease. For PTLD subjects with primary CNS lymphoma, we utilize therapeutic paradigms similar to immunocompetent CNS lymphoma using high-dose methotrexate-based therapy with concurrent rituximab therapy and sequential high-dose cytarabine. Finally, novel therapeutic strategies, especially adoptive immunotherapy, should continued to be explored.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Doak PB, Montgomerie JZ, North JD, et al. Recticulum cell sarcoma after renal homotranplantation and azathioprine and prednisone therapy. Br Med J. 1968;4:746–8.

    Article  PubMed  CAS  Google Scholar 

  2. Opelz G, Henderson R. Incidence of non-hodgkin lymphoma in kidney and heart transplant recipients. Lancet. 1993;342:1514–6.

    Article  PubMed  CAS  Google Scholar 

  3. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis. 2001;3:70–8.

    Article  PubMed  CAS  Google Scholar 

  4. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant. 2004;4:222–30.

    Article  PubMed  Google Scholar 

  5. Caillard S, Lelong C, Pessione F, et al. Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry. Am J Transplant. 2006;6:2735–42.

    Article  PubMed  CAS  Google Scholar 

  6. Hartmann C, Schuchmann M, Zimmerman T. Posttransplant lymphoproliferative disease in liver transplant patients. Curr Infect Dis Rep. 2011;13:53–9.

    Article  PubMed  Google Scholar 

  7. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633–9.

    PubMed  CAS  Google Scholar 

  8. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71:1234–43.

    PubMed  CAS  Google Scholar 

  9. Leblond V, Dhedin N, Mamzer-Bruneel M, et al. Identification of prognostic factors in 61 patients with post transplantation lymphoproliferative disorders. J Clin Oncol. 2005;19:772–8.

    Google Scholar 

  10. Ghobrial IM, Habermann TM, Maurer JM, et al. Prognostic analysis of survival in adult solid organ transplant recipients with post transplantation lymphoproliferative disorders. J Clin Oncol. 2005;23:7574–82.

    Article  PubMed  Google Scholar 

  11. Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid organ transplantation. Transplantation. 2002;74:1095–102.

    Article  PubMed  Google Scholar 

  12. Dharnidharka VR, Sullivan EK, Stablein DM, et al. Risk factors for post-transplantation lymphoproliferative disorders (PTLD) in pediatric kidney transplantation: a report of the North American pediatric renal transplant cooperative study (NAPRTCS). Transplantation. 2001;71:1065–8.

    Article  PubMed  CAS  Google Scholar 

  13. Caillard S, Dharnidharka VR, Agodoa L, et al. post-transplantation lymphoproliferative disorders after renal transplantation in the United States in era of Modern immunosuppression. Transplantation. 2005;80:1233–43.

    Article  PubMed  CAS  Google Scholar 

  14. Evens AM, Roy R, Sterrenberg D, et al. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis and current approaches to therapy. Curr Oncol Rep. 2010;12:383–94.

    Article  PubMed  Google Scholar 

  15. Loren AW, Porter DL, Stadmauer EA, et al. Post-transplantation lymphoproliferative disorder: a review. Bone Marrow Transplant. 2003;31:145–55.

    Article  PubMed  CAS  Google Scholar 

  16. Oton AB, Wang H, Leleu X, et al. Clinical and pathological prognostic markers for survival in adult patients with post-transplantation lymphoproliferative disorders in solid transplant. Leuk Lymphoma. 2008;49:1738–44.

    Article  PubMed  CAS  Google Scholar 

  17. Johnson LR, Nalesnik MA, Swerdlow SH. Impact of Epstein-Barr virus in monomorphimc B-cell post-transplantation lymphoproliferative disorders. Am J Surg Pathol. 2006;30:1604–12.

    Article  PubMed  Google Scholar 

  18. Novoa-Takara L, Perkins SL, Qi D, et al. Histogenic phenotypes of B cells in post-transplantation lymphoproliferative disorders by immunohistochemical analysis correlate with transplant type. Am J Surg Pathol. 2005;123:104–12.

    Google Scholar 

  19. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced post-transplantation lymphoproliferative disorders. Transplantation. 1999;68:1517–25.

    Article  PubMed  CAS  Google Scholar 

  20. Nourse JP, Jones K, Gandhi MK. Epstein-Barr virus related post-transplantation lymphoproliferative disorders: Pathogenetic insights for targeted therapy. Am J Transplant. 2011;11:888–95.

    Article  PubMed  CAS  Google Scholar 

  21. McDonald RA, Smith JM, Ho M, et al. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant. 2008;8:984–9.

    Article  PubMed  CAS  Google Scholar 

  22. Schaffer K, Hasan J, Staines A, et al. Surveillance of EBV viral loads in adult liver transplantation: association with age, gender, time post-transplant and plant indications. Liver Transplant. 2011; In press.

  23. Humar A, Michaels M. AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendation for screening, monitorting and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6:262–74.

    Article  PubMed  CAS  Google Scholar 

  24. Reshefa R, Luskina M, Kamounb M, et al. Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant Recipients. Am J of Transplant. 2011;11:817–25.

    Article  Google Scholar 

  25. Subklewe M, Marquis R, Choquet S, et al. Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation. Transplantation. 2006;82:1093–100.

    Article  PubMed  CAS  Google Scholar 

  26. Pourfarziani V, Einollahi B, Taheri S, et al. Associations of human leukocyte antigen (HLA) haplotypes with risk of developing lymphoproliferative disorders after renal transplantation. Ann Transplant. 2007;12:16–22.

    PubMed  Google Scholar 

  27. Bakker NA, van Imhoff GW, Verschuuren EA, et al. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation. 2005;80:595–9.

    Article  PubMed  CAS  Google Scholar 

  28. Thomas RV, McAulay K, Higgins C, et al. Interferon gamma (IFN-gamma) polymorphism in posttransplantation lymphoproliferative disease. Blood. 2005;106:1502–3 [author reply 1503].

    Article  PubMed  CAS  Google Scholar 

  29. Stern M, Opelz G, Dohler B, Hess C. Natural killer-cell receptor polymorphisms and posttransplantation non-Hodgkin lymphoma. Blood. 2010;115:3960–5.

    Article  PubMed  CAS  Google Scholar 

  30. VanBuskirk AM, Malik V, Xia D, et al. A gene polymorphism associated with posttransplant lymphoproliferative disorder. Transplant Proc. 2001;33:1834.

    Article  PubMed  CAS  Google Scholar 

  31. Lee TC, Savoldo B, Barshes NR, et al. Use of cytokine polymorphisms and Epstein–Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients. Clin Transplant. 2006;20:389–93.

    Article  PubMed  Google Scholar 

  32. Babel N, Vergopoulos A, Trappe RU, et al. Evidence for genetic susceptibility towards development of posttransplant lymphoproliferative disorder in solid organ recipients. Transplantation. 2007;84:387–91.

    Article  PubMed  Google Scholar 

  33. McAulay KA, Haque T, Crawford DH. Tumour necrosis factor gene polymorphism: a predictive factor for the development of post-transplant lymphoproliferative disease. Br J Cancer. 2009;101:1019–27.

    Article  PubMed  CAS  Google Scholar 

  34. Zutter MM, Martin PJ, Shulman HM, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood. 1988;72:520–9.

    PubMed  CAS  Google Scholar 

  35. Nee R, Hurst FP, Dharnidharka VR, et al. Racial variation in the development of post-transplantation lymphoproliferative disorders after renal transplantation. Transplantation. 2011;92:190–5.

    Article  PubMed  Google Scholar 

  36. Buda A, Caforio A, Calabrese F, et al. Lymphoproliferative disorders in heart transplant recipients: Role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection. Transpl Int. 2000;13:S402–5.

    PubMed  Google Scholar 

  37. Manez R, Breinig MC, Linden P, et al. Posttransplantation lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: a role of cytomegalovirus disease. J Infect Dis. 1997;176:1462–7.

    Article  PubMed  CAS  Google Scholar 

  38. Tsao L, Hsi ED. The clinicopathologic spectrum of posttransplantation lymphoproliferative disorders. Arch Path Lab Med. 2007;131:1209–18.

    PubMed  Google Scholar 

  39. Swerdlow SH, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.

    Google Scholar 

  40. Swerdlow SH. T-cell and NK-cell posttransplantation lymphoproliferative disorders. Am J Clin Pathol. 2007;127:887–95.

    Article  PubMed  Google Scholar 

  41. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post-transplantation lymphoproliferative disorder in solid organ recipients—BCSH and BTS guidelines. Br J Haematol. 2010;149:675–92.

    Article  PubMed  Google Scholar 

  42. Vegso G, Hajdu M, Sebestyen A. Lymphoproliferative disorders after solid organ transplantation—classification, incidence, risk factors, early detection and treatment options. Pathol Oncol Res. 2011;17:443–54.

    Article  PubMed  Google Scholar 

  43. Djokic M, Le Beau MM, Swinnen LJ, et al. Post-transplant lymphoproliferative disorder subtypes correlate with different recurring chromosomal abnormalities. Genes Chromosomes Cancer. 2006;45:313–8.

    Article  PubMed  CAS  Google Scholar 

  44. Nelson BP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus negative post-transplant lymphoproliferative disorders. A distinct entity? Am J Surg Pathol. 2000;24:375–85.

    Article  PubMed  CAS  Google Scholar 

  45. Leblond V, Davi F, Charolette F, et al. Post-transplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol. 1998;16:2052–9.

    PubMed  CAS  Google Scholar 

  46. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: Outcomes and prognostic factors in the modern era. J Clin Oncol. 2010;28:1038–46.

    Article  PubMed  Google Scholar 

  47. Weissmann DJ, Ferry JA, Harris NL, et al. Post-transplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol. 1995;103:748–55.

    PubMed  CAS  Google Scholar 

  48. Buell JF, Gross TG, Hanaway MJ, et al. Posttransplantation lymphoproliferative disorder: significance of central nervous system involvement. Transplant Proc. 2005;37:954–5.

    Article  PubMed  CAS  Google Scholar 

  49. Penn I, Porat G. Central nervous system lymphomas in organ allograft recipients. Transplantation. 1995;59:240–4.

    PubMed  CAS  Google Scholar 

  50. Cavaliere R, Petroni G, Lopes MB, et al. Primary central nervous system post-transplantation lymphoproliferative disorder. Cancer. 2010;116:863–70.

    Article  PubMed  Google Scholar 

  51. McDiarmid SV, Jordan S, Lee GS, et al. Prevention and preemptive therapy of post-transplant lymphoproliferative disease in pediatric liver recipients. Transplantation. 1998;66:1604–11.

    Article  PubMed  CAS  Google Scholar 

  52. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005;5:2894–900.

    Article  PubMed  CAS  Google Scholar 

  53. Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies. Blood. 2007;109:2571–8.

    Article  PubMed  CAS  Google Scholar 

  54. Starzl TE, Porter KA, Iwatsuki JT, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet. 1984;17:583–7.

    Article  Google Scholar 

  55. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognositic variables and long-term follow-up of 42 adults. Transplantation. 2001;71:1076–88.

    Article  PubMed  CAS  Google Scholar 

  56. Reshef R, Vardhanabhuti S, Luskin MR, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011;11:336–47.

    Article  Google Scholar 

  57. Delucchi A, Valenzeula M, Lillo AM, et al. Early steroid withdrawal in pediatric renal transplant: five years of follow-up. Pediatr Nephrol. 2011;1934–6.

  58. Benkerrou M, Jais JP, Leblond V, et al. Anti B-cell monoclonal antibody treatment of severe posttransplantation lymphoproliferative disorder: prognostic factors and long-term outcome. Blood. 1998;92:3137–47.

    PubMed  CAS  Google Scholar 

  59. Ghobrial IM, Habermann TM, Ristow KM, et al. Prognostic factors in patients with post-transplantation lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma. 2005;46:191–6.

    Article  PubMed  CAS  Google Scholar 

  60. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: result of a prospective multicenter phase 2 study. Blood. 2006;107:3053–7.

    Article  PubMed  CAS  Google Scholar 

  61. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant. 2006;6:569–76.

    Article  PubMed  CAS  Google Scholar 

  62. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in c: a retrospective analysis of 32 patients. Ann Oncol. 2000;11 Suppl 1:113–6.

    Article  PubMed  Google Scholar 

  63. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for post-transplantation lymphoproliferative disorder after solid organ transplantation in adults: long term experience from a single center. Transplantation. 2005;80:1692–8.

    Article  PubMed  CAS  Google Scholar 

  64. Gonzalez-Barca E, Domingo-Domenech E, Capote FJ, et al. Prospective pahase II trial of extended treatment with Rituximab in patients with B-cell post-transplantation lymphoproliferative disease. Haematologica. 2007;92:1489–94.

    Article  PubMed  CAS  Google Scholar 

  65. Trappe R, Choquet S, Oertel SHK, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2011 Dec 13. [epub ahead of print]

  66. Rooney CM, Smith CA. Use of gene-modified virus specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995;345:9–13.

    Article  PubMed  CAS  Google Scholar 

  67. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr-virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–91.

    Article  PubMed  CAS  Google Scholar 

  68. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive post-transplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110:1123–31.

    Article  PubMed  CAS  Google Scholar 

  69. Rooney CM, Smith CA, Ng CYC, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr-virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998;92:1549–55.

    PubMed  CAS  Google Scholar 

  70. Gustaffson A, Levitsky V, Zou J, et al. Epstein-Barr-viral load in bone marrow transplant recipients at risk to develop post-transplantation lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood. 2000;95:807–14.

    Google Scholar 

  71. Fohrer C, Caillard S, Koumarianou A, et al. Long-term survival in post- transplant lymphoproliferative disorders with a dose adjusted ACVBP regimen. Br J Haematol. 2006;134:602–12.

    Article  PubMed  CAS  Google Scholar 

  72. Giraldi E, Provenzi M, Fiocchi R, et al. Fludarabine, cyclophosphamide, doxorubicin, (FCD), and rituximab: a remission induction therapy for aggressive pediatric post- transplant lymphoproliferative disease (PTLD). Pediart Blood Cancer. 2011;57:324–8.

    Article  Google Scholar 

  73. Swinnen LJ, Mullen GM, Carr TJ, et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood. 1995;86:3333–40.

    PubMed  CAS  Google Scholar 

  74. Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases in a single center. J Clin Oncol. 2000;18:3622–32.

    PubMed  CAS  Google Scholar 

  75. Choquet S, Trappe R, Leblond V, et al. CHOP-21 for the treatment of post-transplant lymphoproliferative disorders following solid organ transplantation. Haematologica. 2007;92:273–4.

    Article  PubMed  Google Scholar 

  76. Haddad E, Paczensny S, Leblond V, et al. Treatment of B- lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial. Blood. 2001;97:1590–7.

    Article  PubMed  CAS  Google Scholar 

  77. Davis C, Wood BL, Sabath DE, et al. Interferon-[alpha] treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation. 1998;66:1770–9.

    Article  PubMed  CAS  Google Scholar 

  78. Komrokji RS, Oliva JL, Zand M, et al. Mini-BEAM and autologous hematopoietic stem-cell transplant for treatment of post-transplant lymphoproliferative disorders. Am J Hematol. 2005;79:211–5.

    Article  PubMed  Google Scholar 

  79. Williams KM, Higman MA, Chen AR, et al. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma. Pediatr Blood Cancer. 2008;50:667–70.

    Article  PubMed  Google Scholar 

  80. Bobey NA, Stewart DA, Woodman RC. Successful treatment of posttransplant lymphoproliferative disorder in a renal transplant by autologous peripheral blood stem cell transplantation. Leuk Lymphoma. 2002;43:2421–3.

    Article  PubMed  CAS  Google Scholar 

  81. Mahe B, Moreau P, Le Tortorec S, et al. Autologous bone marrow transplantation for cyclosporine-related lymphoma in a renal transplant patient. Bone Marrow Transplant. 1994;14:645–6.

    PubMed  CAS  Google Scholar 

  82. Taj MM, Messahel B, Mycroft J, et al. Efficacy and tolerability of high-dose methotrexate in central nervous system positive or relapsed lymphoproliferative disease following liver transplant in children. Br J Haematol. 2007;140:191–6.

    Article  Google Scholar 

  83. Evens AM, Choquet S, Kroll A, et al. Primary central nervous system (PCNS) post-transplant lymphoproliferative disease (PTLD): An international report of 65 cases in the modern era. Blood 2011; (in press).

  84. Knight JA, Tsodikov A, Cibrik DM, et al. Lymphoma after solid organ transplantation: Risk, response to therapy and survival at a transplantation center. J Clin Oncol. 2009;27:3354–62.

    Article  PubMed  Google Scholar 

  85. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol. 2005;23:7574–82.

    Article  PubMed  Google Scholar 

  86. Maecker B, Jack T, Zimmermann M, et al. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol. 2007;25:4902–8.

    Article  PubMed  Google Scholar 

Download references

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. The University of Massachusetts Medical School, Worcester, MA, USA

    Deepa Jagadeesh MD, MPH, Bruce A. Woda MD, Jacqueline Draper BS & Andrew M. Evens DO, MSc

  2. Department of Medicine, Division of Hematology/Oncology, University of Massachusetts, Worcester, MA, USA

    Deepa Jagadeesh MD, MPH & Andrew M. Evens DO, MSc

  3. Department of Pathology, University of Massachusetts, Worcester, MA, USA

    Bruce A. Woda MD

  4. Division of Hematology/Oncology, Lymphoma Program, University of Massachusetts, 55 Lake Avenue North, Worcester, MA, 01655, USA

    Deepa Jagadeesh MD, MPH

Authors
  1. Deepa Jagadeesh MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bruce A. Woda MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jacqueline Draper BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrew M. Evens DO, MSc
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrew M. Evens DO, MSc.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jagadeesh, D., Woda, B.A., Draper, J. et al. Post Transplant Lymphoproliferative Disorders: Risk, Classification, and Therapeutic Recommendations. Curr. Treat. Options in Oncol. 13, 122–136 (2012). https://doi.org/10.1007/s11864-011-0177-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-011-0177-x

Keywords

Search

Navigation